Clinical trials: Peripheral T Cells Lymphoma (PTCL)
Relapsed or Refractory Peripheral T-Cell Lymphoma
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL).
- Trial name
- PTCL (NCT02464228)
- Testing
- Tipifarnib
- Where
- 13 sites in United States, South Korea and 1 more
- Volunteers
- 65 people
- Sponsor
- Kura Oncology, Inc.
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
This study will enroll subjects with either Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma(CTCL),including mycosis fungoides (MF) and Sezary Syndrome (SS), who have relapsed after achieving a complete response in…
- Trial name
- NCT01226472
- Testing
- KW-0761
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of GNTbm-38 in adult patients with advanced solid tumors and R/R PTCL.
- Trial name
- NCT07842445
- Testing
- GNTbm-38
- Volunteers
- 70 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
Peripheral T Cell Lymphoma
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
This is a randomized, open-label, active controlled, multi-center, phase 3 clinical study to compare the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with Chidamide in patients with relapsed/refractory…
- Trial name
- NCT04668690
- Testing
- Mitoxantrone Hydrochloride Liposome Injection, Chidamide
- Where
- China
- Volunteers
- 193 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Relapsed or Refractory T-cell Lymphomas
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).
- Trial name
- NCT06035497
- Testing
- BMS-986369
- Where
- 40 sites in Japan
- Volunteers
- 83 people
- Sponsor
- Bristol-Myers Squibb
Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas.
- Conditions
- Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- PXD101-CLN-6 (NCT00274651)
- Testing
- belinostat
- Where
- 15 sites in United States, France and 3 more
- Volunteers
- 53 people
- Sponsor
- Valerio Therapeutics
Lymphoma, Malignant, Non-hodgkin Lymphoma
DS-3201b in Participants With Lymphomas
DS-3201b is an experimental drug that is being investigated in clinical research. Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to…
- Trial name
- NCT02732275
- Testing
- DS-3201b
- Where
- 20 sites in United States, Japan
- Volunteers
- 100 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL)
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Adult patients with Relapsed or Refractory (R/R) Lymphomas, Large Granular Lymphocytic Leukemia (LGL-L)…
- Conditions
- Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L)
- Trial name
- NCT05225584
- Testing
- KT-333
- Where
- 13 sites in United States
- Volunteers
- 56 people
- Sponsor
- Kymera Therapeutics, Inc.
Peripheral T Cell Lymphoma
Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL
This is a phase II open label, two-arm parallel design study of T-CHOP in patients with treatment naïve PTCL. Two doses of tenalisib (400 mg BID and 800 mg BID) will be evaluated in separate groups (Group 1: 400 mg BID and Group…
- Trial name
- NCT05239910
- Testing
- Tenalisib
- Where
- United States
- Sponsor
- Rhizen Pharmaceuticals SA
Peripheral T Cell Lymphoma
The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).
It is a multi-center, prospective, open-label, two-stage optimized design, single-arm, phase II clinical study to evaluate the efficacy and safety of F520 for the treatment of relapsed and refractory peripheral T cell lymphoma…
- Trial name
- NCT04457830
- Testing
- F520
- Volunteers
- 105 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.
- Trial name
- NCT02567656
- Testing
- RP6530
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Rhizen Pharmaceuticals SA
Peripheral T-cell Lymphoma
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy in Korean patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL).
- Trial name
- NCT01689220
- Testing
- SP-02L (darinaparsin for injection)
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Solasia Pharma K.K.
Lymphoma, T-cell, Peripheral
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
The purpose of the study was to assess efficacy, tolerability, safety and pharmacokinetics of Romidepsin in subjects with progressive or relapsed peripheral T-cell lymphoma
- Trial name
- NCT01456039
- Testing
- Romidepsin
- Where
- 17 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Celgene
Peripheral T-cell Lymphoma
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL).
- Trial name
- NCT07234162
- Testing
- Golidocitinib, Chidamide, Gemcitabine
- Where
- 51 sites in China, Taiwan and 1 more
- Volunteers
- 218 people
- Sponsor
- Dizal Pharmaceuticals
Relapsed or Refractory Peripheral T-cell Lymphoma
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.
- Trial name
- NCT05833724
- Testing
- Chidamide
- Where
- 6 sites in Taiwan
- Volunteers
- 33 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
Peripheral T Cell Lymphoma
A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of SHC014748M in patients with relapsed or refractory relapsed or refractory Peripheral T Cell Lymphoma.
- Trial name
- NCT04470141
- Testing
- SHC014748M treatment
- Volunteers
- 130 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Hodgkin Disease, Lymphoma, T-Cell, Peripheral
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma.
- Conditions
- Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
- Trial name
- NCT06254495
- Testing
- PF-08046044/SGN-35C
- Where
- 33 sites in United States, Denmark and 4 more
- Volunteers
- 58 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Peripheral T Cell Lymphoma
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study.
- Trial name
- CRESCENDO (NCT06072131)
- Testing
- Belinostat Injection, Pralatrexate Injection, CHOP
- Where
- 58 sites in United States, Canada and 8 more
- Volunteers
- 504 people
- Sponsor
- Acrotech Biopharma Inc.
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
This study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.
- Trial name
- NCT06909877
- Testing
- HH2853 Tablets
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Adult T-cell Leukemia-Lymphoma, Peripheral T-cell Lymphoma
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
To determine the maximum tolerated dose of lenalidomide in patients with adult T-cell leukemia-lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) who have previously received therapy for ATL and PTCL
- Trial name
- NCT01169298
- Testing
- Lenalidomide
- Where
- 6 sites in Japan
- Volunteers
- 13 people
- Sponsor
- Celgene